Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

p>Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

1.        Ruff, C et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.

2.        Giugliano, RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013.

3.        Ball, J et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–24.

4.    &#
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
(Date:9/22/2014)... Sept. 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... initiated a phase I clinical trial in patients ... safety, tolerability, and immunogenicity of INO-3106. This immunotherapy ... most aerodigestive cancers. Aerodigestive cancers affect ... and parts of the esophagus and windpipe. The ...
(Date:9/22/2014)... , Sept. 22, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... pleased to announce that TUV-SUD and The Medicinal ... (MEB) has granted its request for a ... Neutrolin was initially approved in July 2013 for ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3
(Date:9/22/2014)... September 19, 2014 -- Recent two-generation approaches to ... are receiving increasing attention from researchers, advocates, and ... to enable them to move to jobs that ... early care and education for children, these programs ... However, according to a new report from ...
(Date:9/22/2014)... RESTON, Va. (PRWEB) September 22, 2014 ... (WEDI), the nation’s leading nonprofit authority on ... in healthcare information exchange, announced findings from its ... unique Health Plan Identifier (HPID) within electronic transactions ... Act (HIPAA). WEDI conducted the survey from August ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, ... What can I do to help ensure a healthy baby? ... may play a role in reducing the risk of having ... found that mothers of children with autism were significantly less ... than those whose children seem to be developing normally. ...
(Date:9/22/2014)... 2014 Severe weather can occur with little warning, ... as part of National Preparedness Month, Amica Insurance is ... for the unexpected:, , Build an emergency supply ... and one gallon of water per person per day for at ... plan that includes pets so your family knows what to do ...
(Date:9/22/2014)... The struggles that lie in communication between ... been well-documented—reportedly, language barriers between doctors and patients are ... room and an increased likelihood for fatal consequences and ... the largest medical facility in the Fargo, ND and ... the need for Video Remote Interpreting (VRI), ...
Breaking Medicine News(10 mins):Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Amica Shares Tips for National Preparedness Month 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4
... LONDON: Children who attend day care or play groups ... most common type of childhood leukaemia than those who ... investigating the link. , The new research, to ... Causes and Prevention of Childhood Leukaemia Conference in London, ...
... Retire from Company -, LAVAL, QC, April ... today announced that Claire Brulle, M.D. has been ... Company. Incumbent,Chief Medical Officer Dr. Sylvie Bouchard has ... practicing medicine., "Dr. Brulle brings to Labopharm ...
... Authentidate,Holding Corp. (Nasdaq: ADAT ), ... and web-based services, today announced that United,Seating ... providers of comprehensive,seating and mobility solutions for ... platform from Authentidate(R) to facilitate its,mobility provisioning ...
... TRIANGLE PARK, N.C., April 28 Tryton Medical,Inc. ... Davis as President and,Chief Executive Officer. Founded in ... that are designed to definitively treat bifurcation,lesions., ... 20-year career with,Guidant and Eli Lilly & Company. ...
... (Oakland, Calif.) Diabetes before motherhood more than doubled ... to a Kaiser Permanente study published in the May ... previous studies have looked exclusively at gestational diabetes (diabetes ... baby is born), this is the largest and most ...
... the Universities of Exeter and Coventry have developed the ... the rapid diagnostic tests (RDTs) currently used in the ... suggest that the technique could be as effective as ... potentially viable alternative. The team is now working on ...
Cached Medicine News:Health News:New analysis finds daycare attendance early in life cuts childhood leukemia risk by 30 percent 2Health News:New analysis finds daycare attendance early in life cuts childhood leukemia risk by 30 percent 3Health News:Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer 2Health News:Leading Provider United Seating & Mobility Implements Authentidate's Inscrybe Healthcare Platform to Standardize and Streamline Administrative Processes 2Health News:Leading Provider United Seating & Mobility Implements Authentidate's Inscrybe Healthcare Platform to Standardize and Streamline Administrative Processes 3Health News:Leading Provider United Seating & Mobility Implements Authentidate's Inscrybe Healthcare Platform to Standardize and Streamline Administrative Processes 4Health News:J. Greg Davis Appointed President & Chief Executive Officer of Tryton Medical, Inc. 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 3Health News:Exeter engineers create new technique for malaria diagnosis 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: